Atossa Q3: Cash Falls to $20.6M, Going Concern Reaffirmed as Burn Hits $24.7M
ATOS sits 26% above its 52-week low of $1.7.
Summary
Atossa's Q3 10-Q shows cash down to $20.6 million from $41.3 million at year-end, a $24.7 million nine-month operating burn, and a reaffirmed going-concern warning — additional financing will be needed within twelve months.
Key Events · Earnings and Guidance · ATOS
-
Q3 Net Loss and Cash Position
Nine-month net loss of $23.7 million and a Q3 net loss of $5.6 million; unrestricted cash and equivalents of $20.6 million at September 30, 2026 versus $41.3 million at December 31, 2025.
-
Going Concern Warning Reaffirmed
Management states existing resources will likely be insufficient to fund planned operations for the next twelve months and that substantial doubt exists about the ability to continue as a going concern.
-
Operating Burn Accelerated
Net cash used in operating activities was $24.7 million for the nine months, up $5.5 million from $19.2 million a year earlier, driven by $3.2 million of patent litigation and professional fees plus higher clinical spend.
-
Financing Levers Largely Untapped
The $50.0 million ATM sold only 4,300 shares for $21 thousand net in the nine months; the June 2026 registered direct offering raised $4.0 million net at $3.30 per share with 2.77 million warrants struck at $4.40.
Analysis · ATOS · Life Sciences
Atossa ended September with $20.6 million in unrestricted cash, down from $41.3 million at year-end, after burning $24.7 million in operations over nine months. Management states plainly that existing resources will likely be insufficient to fund planned operations for the next twelve months and that substantial doubt exists about the company's ability to continue as a going concern. That makes the next capital raise the central variable for shareholders: the $50.0 million ATM has barely been used (4,300 shares, $21 thousand), and the June 2026 registered direct offering raised only $4.0 million net. Every dollar raised from here comes at the cost of dilution, and the 2.77 million outstanding warrants struck at $4.40 are far above today's trading level, so they are unlikely to be a near-term cash source. The one offset is the stapled CVR, which gives holders 25% of net proceeds from a future priority review voucher, capped at $50 million — potential non-dilutive value, but contingent on an FDA approval that has not happened.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATOS was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.3M. The 52-week trading range was $1.70 to $14.85. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.